Total Payments
$79,241
2024 Payments
$1,214
Companies
48
Transactions
624
Medicare Patients
41,969
Medicare Billing
$6.6M
Payment Breakdown by Category
Research$65,932 (83.2%)
Food & Beverage$10,440 (13.2%)
Consulting$2,568 (3.2%)
Travel$180.66 (0.2%)
Education$119.89 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $65,932 | 12 | 83.2% |
| Food and Beverage | $10,440 | 606 | 13.2% |
| Consulting Fee | $2,568 | 2 | 3.2% |
| Travel and Lodging | $180.66 | 1 | 0.2% |
| Education | $119.89 | 3 | 0.2% |
Payments by Type
Research
$65,932
12 transactions
General
$13,309
612 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $29,392 | 3 | $0 (2020) |
| Vifor (International) Ltd. | $24,018 | 6 | $0 (2020) |
| Eli Lilly and Company | $12,522 | 3 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $2,172 | 41 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,196 | 57 | $0 (2024) |
| Amgen Inc. | $1,055 | 63 | $0 (2024) |
| AstraZeneca UK Limited | $1,000 | 1 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $991.60 | 80 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $651.07 | 50 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $540.06 | 29 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,214 | 52 | Lexicon Pharmaceuticals, Inc. ($177.78) |
| 2023 | $1,389 | 70 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($166.71) |
| 2022 | $2,489 | 74 | AstraZeneca UK Limited ($1,000) |
| 2021 | $2,522 | 87 | Eli Lilly and Company ($1,097) |
| 2020 | $55,220 | 60 | Novo Nordisk AS ($29,392) |
| 2019 | $13,275 | 84 | Vifor (International) Ltd. ($12,009) |
| 2018 | $1,926 | 116 | AstraZeneca Pharmaceuticals LP ($501.54) |
| 2017 | $1,207 | 81 | Astellas Pharma US Inc ($152.61) |
All Payment Transactions
624 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $21.77 | General |
| 11/19/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.25 | General |
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $23.11 | General |
| 10/29/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: Cardiology | ||||||
| 10/25/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/22/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $26.61 | General |
| 10/09/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/01/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $15.44 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 09/24/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.66 | General |
| 09/03/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 08/27/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $29.55 | General |
| 08/20/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: Cardiology | ||||||
| 08/13/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $15.09 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 08/06/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $32.04 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 07/31/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $16.82 | General |
| Category: Diabetes | ||||||
| 07/23/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $25.02 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/16/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $22.83 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 07/02/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.99 | General |
| 06/27/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.42 | General |
| 06/19/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: Diabetes | ||||||
| 06/18/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/13/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $20.78 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 06/11/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/04/2024 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: Cardiovascular and Metabolism | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| COR-001-02 | Novo Nordisk AS | $29,392 | 3 |
| DIAMOND PAT-CR-302 | Vifor (International) Ltd. | $24,018 | 6 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $12,522 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 45 | 9,814 | 17,428 | $3.1M | $1.6M |
| 2022 | 45 | 9,067 | 15,529 | $2.9M | $1.5M |
| 2021 | 58 | 11,630 | 19,852 | $3.2M | $1.8M |
| 2020 | 60 | 11,458 | 19,884 | $3.0M | $1.7M |
Total Patients
41,969
Total Services
72,693
Medicare Billing
$6.6M
Procedure Codes
228
All Medicare Procedures & Services
228 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,817 | 5,903 | $885,450 | $541,779 | 61.2% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 486 | 486 | $286,740 | $158,016 | 55.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 1,214 | 1,234 | $375,800 | $156,530 | 41.7% |
| 36482 | Chemical destruction of first incompetent vein of arm or leg using imaging guidance | Office | 2023 | 48 | 99 | $237,600 | $123,762 | 52.1% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 932 | 945 | $337,365 | $123,696 | 36.7% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 486 | 976 | $146,400 | $85,818 | 58.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 301 | 960 | $86,402 | $59,984 | 69.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 365 | 445 | $122,375 | $59,635 | 48.7% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 268 | 1,069 | $72,692 | $46,535 | 64.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 301 | 301 | $64,715 | $35,310 | 54.6% |
| 93979 | Ultrasound of aorta, vena cava, groin vessels or bypass grafts | Office | 2023 | 355 | 359 | $75,390 | $29,610 | 39.3% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 488 | 488 | $73,200 | $23,058 | 31.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 149 | 172 | $34,400 | $22,439 | 65.2% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 132 | 139 | $33,055 | $18,812 | 56.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 289 | 304 | $38,000 | $15,643 | 41.2% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 45 | 48 | $14,400 | $10,295 | 71.5% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 55 | 65 | $14,950 | $10,229 | 68.4% |
| 93971 | Ultrasound study of one arm or leg veins with compression and maneuvers | Office | 2023 | 58 | 111 | $16,530 | $9,832 | 59.5% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 138 | 361 | $16,245 | $7,679 | 47.3% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 60 | 298 | $14,900 | $7,658 | 51.4% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 120 | 193 | $13,510 | $7,572 | 56.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 573 | 708 | $26,196 | $7,386 | 28.2% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 183 | 457 | $20,108 | $7,110 | 35.4% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 42 | 42 | $14,280 | $6,025 | 42.2% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 122 | 125 | $21,787 | $5,868 | 26.9% |
About Dr. Lan Luo, MD
Dr. Lan Luo, MD is a Cardiovascular Disease healthcare provider based in Ocala, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1295938975.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lan Luo, MD has received a total of $79,241 in payments from pharmaceutical and medical device companies, with $1,214 received in 2024. These payments were reported across 624 transactions from 48 companies. The most common payment nature is "" ($65,932).
As a Medicare-enrolled provider, Luo has provided services to 41,969 Medicare beneficiaries, totaling 72,693 services with total Medicare billing of $6.6M. Data is available for 4 years (2020–2023), covering 228 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Ocala, FL
- Active Since 06/08/2007
- Last Updated 06/24/2010
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1295938975
Products in Payments
- VELTASSA (Drug) $12,009
- Veltassa (Drug) $12,009
- ENTRESTO (Drug) $2,123
- XARELTO (Drug) $991.60
- ELIQUIS (Drug) $897.09
- Repatha (Biological) $745.07
- BRILINTA (Drug) $716.31
- LifeVest (Device) $651.07
- FARXIGA (Drug) $417.85
- VERQUVO (Drug) $395.78
- NEXLIZET (Drug) $365.17
- JARDIANCE (Drug) $359.95
- PRALUENT (Drug) $325.16
- Corlanor (Drug) $292.15
- PRALUENT ALIROCUMAB INJECTION (Biological) $282.34
- PRALUENT (Biological) $240.16
- LEXISCAN (Drug) $194.91
- MULTAQ (Drug) $190.00
- Vascepa (Drug) $187.22
- ONPATTRO (Drug) $177.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Ocala
Dr. Celso Acevedo, Md, MD
Cardiovascular Disease — Payments: $162,222
Cardiovascular Disease $162,222
Hiroko Beck, Md, MD
Cardiovascular Disease — Payments: $46,884
Cardiovascular Disease $46,884
Dr. Siva Gummadi, M.d, M.D
Cardiovascular Disease — Payments: $32,776
Cardiovascular Disease $32,776
Dr. Gregory Vonmering, Md, MD
Cardiovascular Disease — Payments: $28,465
Cardiovascular Disease $28,465
Dr. Kalpesh Solanki, Do, DO
Cardiovascular Disease — Payments: $25,966
Cardiovascular Disease $25,966
Dr. Rakesh Prashad, M.d, M.D
Cardiovascular Disease — Payments: $18,520
Cardiovascular Disease $18,520